Canon Inc.

2025 Corporate Strategy Conference

Canon Overall Strategy

March 7, 2025

Fujio Mitarai


Chairman & CEO



This presentation contains forward-looking statements with respect to future results, performance and achievements that are subject to risk and uncertainties and reflect management's views and assumptions formed by available information. All statements other than statements of historical fact are statements that could be considered forward-looking statements. When used in this document, words such as "anticipate," "estimate," "expect," "intend," "may," "plan," "project" or "should" and similar expressions, as they relate to Canon, are intended to identify forward-looking statements. Many factors could cause the actual results, performance or achievements of canon to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, changes in general economic and business conditions, changes in currency exchange rates and interest rates, introduction of competing products by other companies, lack of acceptance of new products or services by Canon's targeted customers, inability to meet efficiency and cost reduction objectives, changes in business strategy and various other factors, both referenced in this presentation. Should one or more risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein. Canon does not intend or assume any obligation to update these forward-looking statements.












Review of 2024


Net sales & operating profit



Note: 2024 excludes impact of impairment loss on medical business.

Canon

Performance by industry-oriented business group



Canon



Towards Phase VII (2026 -)

Three Reforms for Greater Growth

Towards greater growth

Three structural reforms

Sales

Review of sales structure

- Reorganization
- Review of sales channel

Medical business

Canon Inc. & CMSC integration

 Dedicating human, technology, know-how and other resources

Production

Review and consolidation of production sites

- Bring back to Japan, high value-added products
- Investigate outsourcing of production

Canon



Cash flow

Acquire new growth drivers

		(Billions of yen)					
		2021	2022	2023	2024	2025	
Op. cash flow		451.0	262.6	451.2	606.8	651.0	
Growth	R&D	287.3	306.7	331.9	337.3	355.0	Actively invest in products and services
investment	СарЕх	177.4	188.5	230.3	237.0	250.0	that will become new pillars
	M&A	31.8	5.9	54.6	32.7	100.0	
	Total	496.4	501.1	616.8	607.0	705.0	Acquire new growth businesses.
Shareholders	Dividend	88.9	119.3	131.0	141.5	149.4	
return	Buybacks	0.0	100.0	100.0	200.0	100.0	
	Total	88.9	219.3	231.0	341.5	249.4	
Debt repaymen	t	174.8	-74.9	-82.0	-126.7	95.0	



Evolution of business portfolio management

[Effort areas by Group]

		Printing	Medical	Imaging	Industrial
	Sales expansion		Ø		Ø
Profitability	Profitability improvement	Ø	Ø		
Asset turnover ratio	Asset reduction	O		0	

[Operating profit/Total assets

[Billions of yen]

2024	Printing	Medical*	Imaging	Industrial	Corp. & Others	Total
Net sales	2,522.7	568.8	937.4	356.5	124.4	4,509.8
Op. profit	289.9	24.7	151.3	68.9	-89.9	444.9
Op. profit ratio	11.5%	4.3%	16.1%	19.3%	-	9.9%
Total assets	1,354.9	421.5	425.5	238.6	3,329.0	5,769.6

*Excludes impact of impairment loss

Sustainability Measures






Realizing a sustainable society

What is expected of companies is to "solve social issues" through business

Canon products and technologies that contribute to solving social issues




FPA-1200NZ2C Semiconductor manufacturing equipment that uses Nanoimprint



Development of high-performance material for perovskite solar cells

Established company-wide organization that promotes sustainability activities

Sustainability Committee








Summary



Promoting change based on the idea that "Change is progress, transformation is advancement"



Note: 2024 figures exclude impairment loss on goodwill linked to medical business.